Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-106 (Taletrectinib) Pharmacokinetics Interaction with Digoxin
NCT05357911Phase 1Completed
- Sponsor
- Nuvation Bio
- Start
- Jul 2021
- Primary completion
- Aug 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of taletrectinib in solid tumor, sponsored by Nuvation Bio. Primary endpoint: Pharmacokinetic exposure parameters of digoxin at 17 days. Started Jul 2021; status: completed.
02
Drugs
taletrectinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05357911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05357911.